GH - Guardant Health, Inc.
After hours:
| Previous close | 32.59 |
| Open | 32.80 |
| Bid | 30.37 x 800 |
| Ask | 34.00 x 800 |
| Day's range | 32.37 - 33.17 |
| 52-week range | 20.67 - 62.75 |
| Volume | |
| Avg. volume | 2,027,409 |
| Market cap | 3.859B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.54 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.00 |
Business WireGuardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
PALO ALTO, Calif., May 31, 2023--Guardant Health will present 17 studies that highlight advances in precision oncology and cancer screening at the 2023 ASCO Annual Meeting in Chicago.
Simply Wall St.Estimating The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
Key Insights The projected fair value for Guardant Health is US$26.40 based on 2 Stage Free Cash Flow to Equity...
- Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
PALO ALTO, Calif., May 26, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Business WireGuardant Health Announces Pricing of Upsized Public Offering of Common Stock
PALO ALTO, Calif., May 23, 2023--Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less und
Business WireGuardant Health Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., May 22, 2023--Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant Hea
Motley FoolWhy Shares of Guardant Health Jumped This Week
Shares of Guardant Health (NASDAQ: GH) were up 14.4% for the week as of Friday afternoon and rose as much as 15.7% for the week, according to data provided by S&P Global Market Intelligence. The stock is up more than 10% so far this year. Two weeks ago, the stock surged because of positive first-quarter earnings that showed revenue up 34%, year over year.
Business WireGuardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
PALO ALTO, Calif., May 17, 2023--Guardant Health secures coverage from major US commercial health insurers for Guardant360® blood test for comprehensive genomic profiling
- Business Wire
Guardant Health Releases Inaugural ESG Report
PALO ALTO, Calif., May 16, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy.
Motley FoolWhy Guardant Health's Shares Climbed This Week
Shares of Guardant Health (NASDAQ: GH) were up 14.8% for the week as of Thursday afternoon and rose as much as 19.8% for the week, according to data provided by S&P Global Market Intelligence. It was a big week for Guardant. On Monday, the biotech company named a new chief operating officer, Ines Dahne-Steuber, and also promoted senior vice president of technology Darya Chudova to chief technology officer.
ZacksGuardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of -3.17% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Guardant Health Reports First Quarter 2023 Financial Results
PALO ALTO, Calif., May 09, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023.
Business WireGuardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
PALO ALTO, Calif., May 09, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, "Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population" (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC).
Business WireGuardant Health Announces Additions to Leadership Team
PALO ALTO, Calif., May 08, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer.
- Business Wire
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
PALO ALTO, Calif., May 05, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m. PT.
ZacksGuardant Health (GH) Expected to Beat Earnings Estimates: Should You Buy?
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
PALO ALTO, Calif., April 27, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.
ZacksDown -6.66% in 4 Weeks, Here's Why You Should You Buy the Dip in Guardant Health (GH)
Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Business WireGuardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
PALO ALTO, Calif., & SAN FRANCISCO, April 25, 2023--Guardant Health and Parker ICI will study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment.
Business WireGuardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
PALO ALTO, Calif., April 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.
ZacksWall Street Analysts Predict a 123.55% Upside in Guardant Health (GH): Here's What You Should Know
The mean of analysts' price targets for Guardant Health (GH) points to a 123.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Business Wire
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
PALO ALTO, Calif., April 19, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Business WireGuardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
PALO ALTO, Calif., April 18, 2023--Guardant Health receives Medicare coverage for Guardant360 Response™ to monitor cancer patient response to immunotherapy
Business WireGuardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
PALO ALTO, Calif., April 11, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.
- Simply Wall St.
Guardant Health, Inc. (NASDAQ:GH) insiders placed bullish bets worth US$5.0m in the last 12 months
Quite a few insiders have dramatically grown their holdings in Guardant Health, Inc. ( NASDAQ:GH ) over the past 12...
ZacksHere's Why Guardant Health (GH) Looks Ripe for Bottom Fishing
Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.